Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor, demonstrating an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line, positioning it as a valuable agent for DLBCL research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor, demonstrating an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line, positioning it as a valuable agent for DLBCL research [1]. |
Targets&IC50 | IRAK4:8.7 nM |
In vitro | IRAK4-IN-27 (Compound 22, 72 h) demonstrated antiproliferative activity in both MYD88 L265P DLBCL cell line (OCI-LY10, IC 50 = 0.248 μM) and MYD88 wild-type cell lines (U2932, IC 50 = 1.251 μM; and GM00637, IC 50 = 1.520 μM). IRAK4-IN-27 (0.5 μM and 1 μM, for 24 and 48 h, respectively) induced apoptosis in OCI-LY10 cells. The compound (0.03-3 μM) inhibited IRAK4 phosphorylation and subsequent signaling pathways in OCI-LY10 cells. Additionally, combination of IRAK4-IN-27 (0.1 μM and 0.2 μM, 48 h) with Ibrutinib suppressed OCI-LY10 cell growth and induced apoptosis. [1] |
Molecular Weight | 430.46 |
Formula | C23H22N6O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IRAK4-IN-27 Immunology/Inflammation NF-Κb IRAK inhibitor inhibit